Galmed Pharmaceuticals Ltd (GLMD)
2.90
-0.04
(-1.36%)
USD |
NASDAQ |
Jan 10, 16:00
2.86
-0.04
(-1.38%)
After-Hours: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 4.805M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -47.06% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.4607 |
Price to Book Value | 0.2606 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.79% |
Profile
Edit
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
URL | https://www.galmedpharma.com |
Investor Relations URL | http://galmedpharma.investorroom.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Jan. 14, 2025 (est.) |
Last Earnings Release | Aug. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
URL | https://www.galmedpharma.com |
Investor Relations URL | http://galmedpharma.investorroom.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Jan. 14, 2025 (est.) |
Last Earnings Release | Aug. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |